Metformin, a medication commonly used to treat insulin resistance and type 2 diabetes, has shown early promise in improving mood symptoms in treatment-resistant bipolar disorder, particularly in patients with metabolic dysfunction. Its effects may be linked to its ability to regulate blood sugar and activate AMPK, a key energy-regulating enzyme involved in bipolar disorder pathophysiology.